NCT04343768View on ClinicalTrials.gov

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 9, 2020

Primary Completion Date

April 27, 2020

Study Completion Date

April 27, 2020

Conditions
COVID-19
Interventions
DRUG

Hydroxychloroquine

This Drug will be used in all arms.

DRUG

Lopinavir / Ritonavir

This Drug will be used in all arms.

DRUG

Interferon Beta-1A

This drug will be only used in Arm 1.

DRUG

Interferon Beta-1B

This drug will be only used in Arm 2.

Trial Locations (1)

Unknown

Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran

All Listed Sponsors
lead

Shahid Beheshti University of Medical Sciences

OTHER

NCT04343768 - An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial | Biotech Hunter | Biotech Hunter